Infographics

Cardiovascular Prevention Strategy

Read more about the article Cardiovascular Prevention Strategy
Cardiovascular Prevention

CardioVascular Prevention 4 + 2 = CV Prevention 4 Steps of Risk Stratification Qualitative Risk ApproximationIdentify major risk factors, initiate counseling, and education. Quantitative Risk EstimationUse a validated model, such as Pooled Cohort Equations in the United States. Risk Enhancing FactorsFor individuals with intermediate risk, assess additional poorly represented factors.…

Continue ReadingCardiovascular Prevention Strategy

Causes of Hypertriglyceridemia

Causes of Hypertriglyceridemia This infographic provides an overview of hypertriglyceridemia, the most common dyslipidemia affecting about 30% of the population. Hypertriglyceridemia often begins at levels of ≥150 mg/dl, though even high-normal values (100-140 mg/dl) may carry increased cardiovascular risk. Key causes are summarized with the mnemonic "High Lipids Cause Morbidity":…

Continue ReadingCauses of Hypertriglyceridemia

Non-Statin Lipid Lowering Agents

Non-Statin Lipid Lowering Agents This table provides an overview of various non-statin lipid-lowering agents, summarizing their mechanisms, lipid-lowering efficacy, impact on major adverse cardiovascular events (MACE), advantages, and disadvantages. Drug Classes Covered: Bempedoic Acid Inclisiran PCSK9 Inhibitors (Evolocumab, Alirocumab) Ezetimibe Bile Acid Sequestrants Niacin Fibrates Omega-3 Fatty Acids (EPA) Each…

Continue ReadingNon-Statin Lipid Lowering Agents

LDL-C vs ApoB

LDL-C vs Apo-B This infographic reveals how LDL-C (low-density lipoprotein cholesterol) concentrations may not tell the full story about cardiovascular risk. It explains that LDL particles can vary in size and density, with smaller, denser particles linked to increased risk of atherosclerosis. These misleading LDL-C values can underestimate cardiovascular risk…

Continue ReadingLDL-C vs ApoB

End of content

No more pages to load